Association of iron therapy with incidence of chronic kidney disease.
albuminuria
chronic kidney disease
eGFR
iron replacement
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
09
08
2023
received:
04
05
2023
accepted:
16
08
2023
medline:
9
11
2023
pubmed:
5
9
2023
entrez:
5
9
2023
Statut:
ppublish
Résumé
We investigated the association of oral iron replacement with the incidence of chronic kidney disease (CKD) in a population with normal kidney function to study the effects of iron replacement on the development of new onset CKD. In a national cohort of US Veterans with no pre-existing CKD, we identified 33 894 incident new users of oral iron replacement and a comparable group of 112 780 patients who did not receive any iron replacement during 2004-2018. We examined the association of oral iron replacement versus no iron replacement with the incidence of eGFR <60 mL/min/1.73 m In the cohort of 146 674 patients, a total of 18 547 (13%) patients experienced incident eGFR <60 mL/min/1.73 m Oral iron replacement is associated with higher risk of new onset CKD. The long-term kidney safety of oral iron replacement should be tested in clinical trials.
Substances chimiques
Creatinine
AYI8EX34EU
Iron
E1UOL152H7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
872-880Subventions
Organisme : US Department of Veterans Affairs Health Services Research and Development Service (HSR&D)
ID : I01HX002680
Organisme : Memphis and Long Beach VA Medical Centers
Organisme : Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center
Informations de copyright
© 2023 John Wiley & Sons Ltd. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Références
Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123(5):615-624.
Dunne JR, Malone D, Tracy JK, Gannon C, Napolitano LM. Perioperative anemia: an independent risk factor for infection, mortality, and resource utilization in surgery. J Surg Res. 2002;102(2):237-244.
Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol. 2008;52(7):501-511.
Brabin BJ, Premji Z, Verhoeff F. An analysis of anemia and child mortality. J Nutr. 2001;131(2S-2):636S-645S. discussion 646S-648S.
Stoltzfus RJ. Iron deficiency: global prevalence and consequences. Food Nutr Bull. 2003;24(4 Suppl):S99-S103.
Brabin BJ, Hakimi M, Pelletier D. An analysis of anemia and pregnancy-related maternal mortality. J Nutr. 2001;131(2S-2):604S-614S. discussion 614S-615S.
Gafter-Gvili A, Schechter A, Rozen-Zvi B. Iron deficiency anemia in chronic kidney disease. Acta Haematol. 2019;142(1):44-50.
Zumbrennen-Bullough K, Babitt JL. The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol Dial Transplant. 2014;29(2):263-273.
Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. 2006;69(3):560-564.
Van Swelm RPL, Wetzels JFM, Swinkels DW. The multifaceted role of iron in renal health and disease. Nat Rev Nephrol. 2020;16(2):77-98.
Drake KA, Sauerbry MJ, Blohowiak SE, Repyak KS, Kling PJ. Iron deficiency and renal development in the newborn rat. Pediatr Res. 2009;66(6):619-624.
Zhu Y, Liu X, Li N, et al. Association between iron status and risk of chronic kidney disease in Chinese adults. Front Med (Lausanne). 2019;6:303.
Babitt JL, Eisenga MF, Haase VH, et al. Controversies in optimal anemia management: conclusions from a kidney disease: improving global outcomes (KDIGO) conference. Kidney Int. 2021;99(6):1280-1295.
Kovesdy CP, Kalantar-Zadeh K. Iron therapy in chronic kidney disease: current controversies. J Ren Care. 2009;35(Suppl 2):14-24.
Shepshelovich D, Rozen-Zvi B, Avni T, Gafter U, Gafter-Gvili A. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis. Am J Kidney Dis. 2016;68(5):677-690.
Rydzewska-Rosolowska A, Sroka N, Kakareko K, Rosolowski M, Zbroch E, Hryszko T. The links between microbiome and uremic toxins in acute kidney injury: beyond gut feeling-a systematic review. Toxins (Basel). 2020;12(12):788.
Sumida K, Lau WL, Kovesdy CP, Kalantar-Zadeh K, Kalantar-Zadeh K. Microbiome modulation as a novel therapeutic approach in chronic kidney disease. Curr Opin Nephrol Hypertens. 2021;30(1):75-84.
Kortman GA, Raffatellu M, Swinkels DW, Tjalsma H. Nutritional iron turned inside out: intestinal stress from a gut microbial perspective. FEMS Microbiol Rev. 2014;38(6):1202-1234.
Hassan W, Shrestha P, Sumida K, et al. Association of uric acid-lowering therapy with incident chronic kidney disease. JAMA Netw Open. 2022;5(6):e2215878.
VA Information Resource Center. VIReC Resource Guide. VA Corporate Data Warehouse. U.S. Dept. of Veterans Affairs, Health Services Research and Development Service, VA Information Resource Center; 2012.
US Department of Veterans Affairs, VA Information Resource Center (VIReC). VIReC Research User Guide: VHA Pharmacy Prescription Data. VIReC; 2008.
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
Kovesdy CP, Alrifai A, Gosmanova EO, et al. Age and outcomes associated with BP in patients with incident CKD. Clin J Am Soc Nephrol. 2016;11(5):821-831.
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
Sumida K, Nadkarni GN, Grams ME, et al. Conversion of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant-based meta-analysis. Ann Intern Med. 2020;173(6):426-435.
Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565-574. discussion 575-567.
Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825-830.
Labrecque JA, Swanson SA. Target trial emulation: teaching epidemiology and beyond. Eur J Epidemiol. 2017;32(6):473-475.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of competing risk. J Am Stat Assoc. 1999;94:496-509.
Li F, Thomas LE, Li F. Addressing extreme propensity scores via the overlap weights. Am J Epidemiol. 2019;188:250-257.
Thomas LE, Li F, Pencina MJ. Overlap weighting: A propensity score method that mimics attributes of a randomized clinical trial. JAMA. 2020;323:2417-2418.
Mathur MB, Ding P, Riddell CA, VanderWeele TJ. Website and R package for computing E-values. Epidemiology. 2018;29(5):e45-e47.
VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268-274.
Haneuse S, VanderWeele TJ, Arterburn D. Using the E-value to assess the potential effect of unmeasured confounding in observational studies. Jama. 2019;321(6):602-603.
Clevenger B, Gurusamy K, Klein AA, Murphy GJ, Anker SD, Richards T. Systematic review and meta-analysis of iron therapy in anaemic adults without chronic kidney disease: updated and abridged Cochrane review. Eur J Heart Fail. 2016;18(7):774-785.
Das SN, Devi A, Mohanta BB, Choudhury A, Swain A, Thatoi PK. Oral versus intravenous iron therapy in iron deficiency anemia: an observational study. J Family Med Prim Care. 2020;9(7):3619-3622.
Okam MM, Koch TA, Tran MH. Iron deficiency anemia treatment response to oral iron therapy: a pooled analysis of five randomized controlled trials. Haematologica. 2016;101(1):e6-e7.
Jankowska EA, Tkaczyszyn M, Suchocki T, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail. 2016;18(7):786-795.
Anker SD, Kirwan BA, van Veldhuisen DJ, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018;20(1):125-133.
Lewis GD, Malhotra R, Hernandez AF, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. Jama. 2017;317(19):1958-1966.
Caravita S, Faini A, Vignati C, et al. Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure. Eur J Heart Fail. 2022;24(10):1940-1949.
Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S, United States Iron Sucrose Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68(6):2846-2856.
Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol. 2006;26(5):445-454.
Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant. 2001;16(5):967-974.
Charytan C, Qunibi W, Bailie GR, Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005;100(3):c55-c62.
Agarwal R. Nonhematological benefits of iron. Am J Nephrol. 2007;27(6):565-571.
Halon-Golabek M, Borkowska A, Herman-Antosiewicz A, Antosiewicz J. Iron metabolism of the skeletal muscle and neurodegeneration. Front Neurosci. 2019;13:165.
Davies KJ, Donovan CM, Refino CJ, Brooks GA, Packer L, Dallman PR. Distinguishing effects of anemia and muscle iron deficiency on exercise bioenergetics in the rat. Am J Physiol. 1984;246(6 Pt 1):E535-E543.
Neidlein S, Wirth R, Pourhassan M. Iron deficiency, fatigue and muscle strength and function in older hospitalized patients. Eur J Clin Nutr. 2021;75(3):456-463.
Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int. 2004;66(1):144-156.
Abbate M, Montemayor S, Mascaro CM, et al. Albuminuria is associated with hepatic iron load in patients with non-alcoholic fatty liver disease and metabolic syndrome. J Clin Med. 2021;10(14):3187.
Akatsu H, Manabe T, Kawade Y, et al. Iron deposition in autopsied liver specimens from older patients receiving intravenous iron infusion. PloS One. 2020;15(8):e0237104.
Marks ES, Bonnemaison ML, Brusnahan SK, et al. Renal iron accumulation occurs in lupus nephritis and iron chelation delays the onset of albuminuria. Sci Rep. 2017;7(1):12821.
Reis KA, Guz G, Ozdemir H, et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int Heart J. 2005;46(2):255-264.
Ma J, Zhang H, Chen Y, Liu X, Tian J, Shen W. The role of macrophage iron overload and ferroptosis in atherosclerosis. Biomolecules. 2022;12(11):1702.
Xiao L, Luo G, Guo X, et al. Macrophage iron retention aggravates atherosclerosis: evidence for the role of autocrine formation of hepcidin in plaque macrophages. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865(2):158531.
Michelis R, Gery R, Sela S, et al. Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant. 2003;18(5):924-930.
Charytan DM, Pai AB, Chan CT, et al. Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol. 2015;26(6):1238-1247.
Sumida K, Kovesdy CP. The gut-kidney-heart axis in chronic kidney disease. Physiol Int. 2019;106(3):195-206.
Sumida K, Molnar MZ, Potukuchi PK, et al. Constipation and incident CKD. J Am Soc Nephrol. 2017;28(4):1248-1258.
Sumida K, Molnar MZ, Potukuchi PK, et al. Constipation and risk of death and cardiovascular events. Atherosclerosis. 2019;281:114-120.